Comparative CD4 T-Cell Responses of Reverse Transcriptase Inhibitor Therapy With or Without Nelfinavir Matched for Viral Exposure

REFERENCES

• Palella FJ, Delaney KM, Moorman A, et al. Declining mor-bidity and mortality among patients with advanced human immunodeficiency virus syndrome. N Engl J Med. 1998;338:853–860.
   PubMed Web of Science ®Google Scholar
• Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collabo-rative Ritonavir Study Group. N Engl J Med. 1995;333: 1528–1533.
   PubMed Web of Science ®Google Scholar
• Gulick RM, Mellors JW, Haylir D, et al. Treatment with indinavir, zidovudine, and lumivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734–739.
   PubMed Web of Science ®Google Scholar
• Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific pro-tease inhibitor, ritonavir. J Infect Dis. 1996;173:321–329.
   PubMed Web of Science ®Google Scholar
• Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeosta-sis and function in advanced HIV disease. Science. 1997;277:112–116.
   PubMed Web of Science ®Google Scholar
• Angel JB, Kumar A, Parato K, et al. Improvement in cell-mediated immune function during potent anti-human im-munodeficiency virus therapy with ritonavir plus saquinavir. J Infect Dis. 1998;177:898–904.
   PubMed Web of Science ®Google Scholar
• Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med. 1996;334:1011–1017.
   PubMed Web of Science ®Google Scholar
• Hirsch M, Steigbigel R, Staszewski S, et al. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. J Infect Dis. 1999;180:659–665.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy. AIDS. 1999;13:F35—F43.
   PubMed Web of Science ®Google Scholar
• Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet. 1998;351:723–724.
   PubMed Web of Science ®Google Scholar
• Levitz SM. Improvement in CD4+ cell counts despite per-sistently detectable HIV load. N Engl J Med. 1998;338:1074–1075.
   PubMed Web of Science ®Google Scholar
• Carr A, Emery S, Kelleher A, Law M, Cooper DA. CD8+ lymphocyte responses to antiretroviral therapy of HIV in-fection. J Acquired Immune Defic Syndr Hum Retrovirol. 1996;13:320–326.
   PubMedGoogle Scholar
• Cohen J. Failure isn't what it used to be...but neither is success. Science. 1998;279:1133–1134.
   PubMed Web of Science ®Google Scholar
• Atkinson B, Isaacson J, Knowles M, Mazabel E, Patick AK. Correlation between human immunodeficiency virus geno-typic resistance and virologic response in patients receiv-ing nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine. J Infect Dis. 2000;182:420–427.
   PubMed Web of Science ®Google Scholar
• Conant M, Markowitz M, Hurley A, Ho D, Peterkin J, Chapman S. A randomized phase ll dose range-finding study of the HIV protease inhibitor Viracept as monotherapy in HIV positive patients. In: 11th International Conference on AIDS; July 7–12, 1996; Vancouver, British Columbia. Abstract Tu.B.2129.
   Google Scholar
• Clendeninn N, Quart B, Anderson R, Knowles M, Chang Y. Analysis of long-term virologic data from the Viracept 511 protocol using 3 HIV-RNA assays [Abstract 372]. In: Pro-gram and abstracts of the Fifth Conference on Retroviruses and Opportunistic Infections; 1998; Chicago.
   Google Scholar
• Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infec-tion. Ann Intern Med. 1997;126:946–954.
   PubMed Web of Science ®Google Scholar
• Arnaout RA, Lloyd AL, O'Brien TR, Goedert JJ, Leonard JM, Nowak MA. A simple relationship between viral load and survival time in HIV-1 infection. Proc Natl Acad Sci USA. 1999;96:11549–11553.
   PubMed Web of Science ®Google Scholar
• O'Brien TR, Blattner WA, Waters D, et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA. 1996;276:105–110.
   PubMed Web of Science ®Google Scholar
• Mellors JW, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272:1167–1170.
   PubMed Web of Science ®Google Scholar
• Saksela K, Stevens CE, Rubinstein P, Taylor PE, Baltimore D. HIV-1 messenger RNA in peripheral blood mononuclear cells as an early marker of risk for progression to AIDS. Ann Intern Med. 1995;123:641–648.
   PubMed Web of Science ®Google Scholar
• O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med. 1996;334:426–431.
   PubMed Web of Science ®Google Scholar
• Wu H, Kuritzkes DR, McClernon DR, et al. Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: Relationships to host factors, cellular restoration and virologic end points. J Inl Dis. 1999;179:799–807.
   PubMed Web of Science ®Google Scholar
• Renaud M, Katlama C, Mallet A, et al. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. AIDS. 1999;13:669–676.
   PubMed Web of Science ®Google Scholar
• Miller V, Mocroft A, Reiss P, et al. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: Results from the EuroSIDA Study. Ann Intern Med. 1999;130:570–577.
   PubMed Web of Science ®Google Scholar
• Notermans D, Goudsmit J, Danner S, de Wolf F, Perelson A, Mittler J. Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regi-men. Cell Death Dill. 1998;6: 420–432.
   Google Scholar
• Badley AD, Pilon AA, Landay A, Lynch DH. Mechanisms of HIV associated lymphocyte apoptosis. Blood. 2000; 96:2951–2964.
   PubMed Web of Science ®Google Scholar
• Phenix BN, Angel JB, Mandy F, et al. Decreased HIV-associated T cell apoptosis by HIV protease inhibitors. AIDS Res Hum Retroviruses. 1999;16:559–567.
   Web of Science ®Google Scholar
• Sloand EM, Kumar PN, Kim S, Chaudhuri A, Weichold FF, Young NS. Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo. Blood. 1999;94:1021–1027.
   PubMed Web of Science ®Google Scholar
• Badley AD, Parato K, Cameron DW, et al. Dynamic correla-tion of apoptosis and immune activation during treatment of HIV infection. Cell Death Dill. 1999;6:420–432.
   PubMed Web of Science ®Google Scholar
• Badley AD, Dockrell DH, Algeciras A, et al. In vivo analysis of Fas/FasL interactions in HIV-infected patients. J Clin Invest. 1998;102:79–87.
   PubMed Web of Science ®Google Scholar
• Kotler DP, Shimada T, Snow G, et al. Effect of combination antiretroviral therapy upon rectal mucosal HIV RNA burden and mononuclear cell apoptosis. AIDS. 1998;12:597–604.
   PubMed Web of Science ®Google Scholar
• Johnson N, Parkin JM. Anti-retroviral therapy reverses HIV-associated abnormalities in lymphocyte apoptosis. Clin Exp Immunol. 1998;113:229–234.
   PubMed Web of Science ®Google Scholar
• Aries SP, Weyrich K, Schaaf B, Hansen F, Dennin RH, Dalhoff K. Early T-cell apoptosis and Fas expression during antiretroviral therapy in individuals infected with human im-munodeficiency virus-1. Scand J Immunol. 1998;48:86–91.
   PubMed Web of Science ®Google Scholar
• Balfour HH. Antiviral drugs. N Engl J Med. 1999;340:1255–1268.
   PubMed Web of Science ®Google Scholar
• Kohl N, Emini E, Schleif W, et al. Active human immunode-ficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA. 1988;85:4686–4690.
   PubMed Web of Science ®Google Scholar
• Flexner C, Broyles S, Chakrabarti S, Moss B. Characteriza-tion of human immunodeficiency virus gag/pol gene prod-ucts expressed by recoombinant vaccinia viruses. Virol-ogy. 1988;166:339–349.
   PubMed Web of Science ®Google Scholar
• Debouck C. The HIV-1 protease as a therapeutic target for AIDS. AIDS Res Hum Retroviruses. 1992;8:153–164.
   PubMed Web of Science ®Google Scholar
• Overton H, McMillan D, Gridley S, Brenner J, Redshaw S, Mills J. Effect of two novel inhibitors of the human immuno-deficiency virus protease on the maturation of the HIV gag and gag-pol polyproteins. Virology. 1990;179:508–511.
   PubMed Web of Science ®Google Scholar
• Humphrey RW, Ohagen A, Davis DA, et al. Removal of human immunodeficiency virus type 1 (HIV-1) protease in-hibitors from preparations of immature HIV-1 virions does not result in an increase in infectivity or the appearance of mature morphology. Antimicrob Agents Chemother. 1997;41:1017–1023.
   PubMed Web of Science ®Google Scholar
• Andreoni M, Sarmati L, Ercoli L, et al. Correlation between changes in plasma HIV RNA levels and in plasma infectivity in response to antiretroviral therapy. AIDS Res Hum Retroviruses. 1997;13:555–561.
   PubMed Web of Science ®Google Scholar
• Martinez-Picado J, Savara AV, Sutton L, D'Aquila RT. Rep-licative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol. 1999;73:3744–3752.
   PubMed Web of Science ®Google Scholar
• Croteau G, Doyon L, Thibeault D, McKercher G, Pilotte L, Lamarre D. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol. 1997;71:1089–1096.
   PubMed Web of Science ®Google Scholar
• Kuroda MJ, El-Farrash MA, Choudhury S, Harada S. Im-paired infectivity of HIV-1 after a single point mutation in the POL gene to escape the effect of a protease inhibitor in vitro. Virol. 1995;210:212–216.
   PubMed Web of Science ®Google Scholar
• Zennou V, Mammano F, Paulous S, Mathez D, Clevel F. Loss of viral fitness associated with multiple gag and gag-pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibi-tors in vivo. J Virol. 1998;72:3300–3306.
   PubMed Web of Science ®Google Scholar
• Mammano F, Petit C, Clevel F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Pheno-typic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol. 1998;72:7632–7637.
   PubMed Web of Science ®Google Scholar
• Garcia F, Plana M, Vidal C, et al. Dynamics of viral load rebound and immunological changes after stopping effec-tive antiretroviral therapy. AIDS. 1999;13:F79—F86.
   PubMed Web of Science ®Google Scholar
• Hawley-Foss N, Mbisa G, Lum JJ, et al. Effect of therapy cessation during a discordant response to HAART: Impli-cations for scheduled therapeutic interruptions. Clin Inf Dis. In press.
   PubMed Web of Science ®Google Scholar